RNU7-26P

Across TCGA pan-cancer cohorts, RNU7-26P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNU7-26P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RNU7-26P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU7-26P is over-expressed in tumor.

BRCA, PRAD, and ESCA are the cancer types where RNU7-26P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU7-26P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	+0.233	<.001	6	view →
PRAD	All	All	+0.148	.035	2	view →
ESCA	All	All	+0.852	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RNU7-26P–BRCA

Open the BRCA breakdown →